INTERVIEW WITH JOE O'SULLIVAN
Assessing the Aging Population and Treatment Considerations for Prostate Cancer

INTERVIEW WITH NICHOLAS JAMES
Systemic Therapies for Node-Positive Non-Metastatic Castration Resistant Prostate Cancer

INTERVIEW WITH ROSALIND EELES
Finding the Full Spectrum of Genetic Variants in Advanced Prostate Cancer

INTERVIEW WITH MATTHEW SMITH
Prolonging Time to Metastatic Disease, The SPARTAN Study

Videos
State-of-the-industry video lectures by leading urology experts
Featured Videos

Evaluation of Oral Pentoxifylline, Colchicine, and Penile Traction for the Management of Peyronie's Disease.

Currently, there are several treatment options for Peyronie disease (PD). Although surgical interventions have better reported outcomes than conservative therapy, surgery is not suitable for all patients with PD. Therefore, oral therapy for PD is still a frequently used treatment due to low cost, convenience and limited side effects. However, current literature on the efficacy of oral therapy in PD is inconclusive. Pentoxifylline and colchicine have both shown some promise though further studies are required to confirm their effectiveness.

The aim of this study was to assess the efficacy of oral therapy for PD, including pentoxifylline and colchicine, coupled with the Andropenis penile traction therapy (PTT) extender on degree of penile curvature and plaque size.

Between March 2015 and June 2018, a prospectively collected database for patients receiving oral therapy for PD (pentoxifylline and/or colchicine) was reviewed.

Collected data variables were compared at baseline and after 6 months of treatment, including degree of curvature, plaque size, and penile Doppler ultrasound parameters (peak systolic velocity, minimum diastolic velocity, and pulsatility index). PTT was applied by the patient for a total of 1 hour per day for 6 months.

A total of 46 patients were involved in this study. Mean age was 56 ± 10 years. There was a significant decrease in the degree of penile curvature after 6 months (55.8º ± 20º vs 41.4º ± 20.8º; P = .03). Likewise, the plaque size decreased significantly from 5.42 ± 2.7 to 2.42 ± 1.71 cm2; P = .0001. There was a significant increase in the peak systolic velocity from 29.8 ± 10.02 to 38.2 ± 11cm/sec; P = .02, whereas no statistically significant difference could be detected regarding end diastolic velocity (M = 0.56 ± 3.1 vs 1.59; P = .415) or pulsatility index (Mdiff = 0.03; CI = -0.06 to 0.12; P = .473). Furthermore, there was no statistically significant difference in medication type of pentoxifylline or colchicine (Mdiff = 17.23; CI = -3.31 to 37.77; P = .09).

Altogether, pentoxifylline and colchicine, taken with concomitant PTT, present a potentially convenient, low cost, and effective treatment for penile curvature and plaque resulting from PD. Prospective randomized trials are still required for better evaluation of the course of PD with patients undergoing conservative management. Ibrahim A, Gazzard L, Alharbi M, et al. Evaluation of Oral Pentoxifylline, Colchicine, and Penile Traction for the Management of Peyronie's Disease. Sex Med 2019;XX:XXX-XXX.

Sexual medicine. 2019 Aug 21 [Epub ahead of print]

Ahmed Ibrahim, Lauren Gazzard, Mohannad Alharbi, Alexis Rompré-Brodeur, Melanie Aube, Serge Carrier

Department of Surgery, Division of Urology, McGill University Health Center, Montreal, Quebec, Canada., Department of Surgery, Division of Urology, McGill University Health Center, Montreal, Quebec, Canada; Department of Urology, College of Medicine, Qassim University, Qassim, Saudi Arabia., Department of Surgery, Division of Urology, McGill University Health Center, Montreal, Quebec, Canada. Electronic address: .

Conference Coverage
 
Recent data from conferences worldwide
  • 2019 Clinical Congress / October 27 -October 31 / San Francisco, California
  • 2019 Annual Meeting / October 29 - November 2 / Abu Dhabi, United Arab Emirates
  • 2019 Annual Congress / October 17 - October 20 / Athens, Greece
  • 2019 Annual Meeting / October 3 - October 5 / Aarhus, Denmark
  • 2019 Annual Congress / September 27 - October 1 / Barcelona, Spain
  • 2019 Biennial Meeting / August 29-31 / Basel, Switzerland
  • 2019 Think Tank / August 8-10 / Washington, DC
  • 2019 Annual Meeting / May 31 - June 6 / Chicago, IL
  • 2019 Annual Meeting / May 3-6 / Chicago, IL
  • 2019 World Congress / May 1-3 / Liverpool, United Kingdom
Journals
Publications focusing on urologic cancer treatments through original manuscripts
E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe